Disclosed positions
| SPDR S&P 500 ETF TR | SPY | TR UNIT | $308,925,000 | 500,000 | SH | Put |
| ZIMMER BIOMET HOLDINGS INC | ZBH | COM | $91,210,000 | 1,000,000 | SH | None |
| BAXTER INTL INC | BAX | COM | $86,298,000 | 2,850,000 | SH | None |
| HUMANA INC | HUM | COM | $73,344,000 | 300,000 | SH | None |
| CVS HEALTH CORP | CVS | COM | $72,429,000 | 1,050,000 | SH | None |
| GLOBUS MED INC | GMED | CL A | $47,216,000 | 800,000 | SH | None |
| ICON PLC | ICLR | SHS | $43,635,000 | 300,000 | SH | None |
| ASCENDIS PHARMA A/S | ASND | SPONSORED ADR | $43,150,000 | 250,000 | SH | None |
| MERCK & CO INC | MRK | COM | $39,580,000 | 500,000 | SH | None |
| GSK PLC | GSK | SPONSORED ADR | $38,400,000 | 1,000,000 | SH | Call |
| PFIZER INC | PFE | COM | $36,360,000 | 1,500,000 | SH | None |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $32,982,000 | 600,000 | SH | None |
| UNITEDHEALTH GROUP INC | UNH | COM | $31,197,000 | 100,000 | SH | None |
| VIATRIS INC | VTRS | COM | $24,557,500 | 2,750,000 | SH | None |
| BROOKDALE SR LIVING INC | BKD | COM | $14,964,000 | 2,150,000 | SH | None |
| ZIMVIE INC | ZIMV | COM | $14,960,000 | 1,600,000 | SH | None |
| APELLIS PHARMACEUTICALS INC | APLS | COM | $14,713,500 | 850,000 | SH | None |
| MYRIAD GENETICS INC | MYGN | COM | $10,620,000 | 2,000,000 | SH | None |
| EVOLENT HEALTH INC | EVH | CL A | $9,571,000 | 850,000 | SH | None |
| CONCENTRA GROUP HOLDINGS PAR | CON | COMMON STOCK | $8,228,000 | 400,000 | SH | None |
| INOGEN INC | INGN | COM | $6,854,250 | 975,000 | SH | None |
| DENALI THERAPEUTICS INC | DNLI | COM | $5,596,000 | 400,000 | SH | None |
| THERAVANCE BIOPHARMA INC | TBPH | COM | $4,963,500 | 450,000 | SH | None |
| ANAPTYSBIO INC | ANAB | COM | $2,775,000 | 125,000 | SH | None |
| ORASURE TECHNOLOGIES INC | OSUR | COM | $2,700,000 | 900,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 2 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.